Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin with Fluorouracil and Leucovorin in Esophageal and Gastric Cardia Carcinoma
NCT00004127Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Feb 2000
- Primary completion
- Oct 2002
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in esophageal carcinoma and gastric cardia carcinoma (GCA), sponsored by University of Chicago. Primary endpoint: Clinical Response Rate at 3 years. Started Feb 2000; status: completed.
02
Drugs
oxaliplatin
03
Conditions
esophageal carcinomagastric cardia carcinoma (GCA)
Beyond the preview
Go deeper on NCT00004127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004127.